8.00 Coffee & Registration

8:30 am Chair’s Opening Remarks

  • Gopi Shanker Director, Head of Psychiatry, Novartis Institutes for Biomedical Research

8:40 am Kick-off Panel Discussion: What is Preventing Experts from Redefining the Field & Developing Transformative Drugs for Psychiatric Patients in Need?

  • Gopi Shanker Director, Head of Psychiatry, Novartis Institutes for Biomedical Research
  • Patricio O’Donnell Executive Medical Director and Head, Neurocircuitry Biomarkers , Takeda Pharmaceuticals

9:20 am Advancing Neurophysiology & Cognition Translational Biomarkers to Drive Drug Development for Neuropsychiatric Disorders

  • Patricio O’Donnell Executive Medical Director and Head, Neurocircuitry Biomarkers , Takeda Pharmaceuticals

9:50 am The Role of the CRO in Patient-Centric CNS Clinical Trials

  • Gary K. Zammit President & CEO, Clinilabs Drug Development Corporation

10.20 Speed Networking & Morning Refreshments

A New Wave of Innovation – Fresh Approaches in Discovery to Yield Novel Mechanisms of Action

11:20 am Impact of GABA Modulation & Role in Developing Episodic Treatments for Mood Disorders

11:50 am Bipolar Depression: Unmet Needs Continue to Exist

  • Sharon Mates Chairman, President & CEO, Intra-Cellular Therapies, Inc.

12:20 pm Developing Rapid-Acting & Sustained Antidepressant Drugs

12.50 Networking Lunch

1:50 pm Exploring Mechanistic Approaches to Treating Neuropsychiatric Disorders such as Depression, Autism & Cognitive Impairment

Deep Dive into Clinical Case Studies for Schizophrenia Candidates

2:20 pm Emergence of the Next Generation of Anti-Psychotics

  • Steve Paul CEO and Chairman, Karuna Therapeutics, Inc

2:50 pm Schizophrenia, A New Treatment Option for Patients

  • Sharon Mates Chairman, President & CEO, Intra-Cellular Therapies, Inc.

15.20 Poster Session & Afternoon Refreshments

Deep Dive Approaches for Treating Post Traumatic Stress Disorder, a Truly Unmet Medical Need

4:00 pm Pioneering Novel Therapeutic Approaches to Address PTSD

4:30 pm BNC210: A Negative Allosteric Modulator of Alpha7 Nicotinic Acetylcholine Receptor in Development for the Treatment of Anxiety, Depression & Post Traumatic Stress Disorder

5:00 pm Developing a PTSD Therapeutic – Phase 3 Clinical Development

5:30 pm Chair’s Closing Remarks

  • Gopi Shanker Director, Head of Psychiatry, Novartis Institutes for Biomedical Research

17.40 End of Day 1: Neuropsychiatric Drug Development Summit